Akso Health Group Raises $53.35M in Private Placement for Working Capital

TL;DR

**Akso Health just raised $53.35M in a private placement, boosting their working capital.**

AI Summary

Akso Health Group announced on January 22, 2024, a private placement where it will sell up to 160,826,730 units to non-U.S. investors. Each unit, priced at $0.3317, includes one ordinary share and a warrant to purchase another share at an initial exercise price of $0.4146. This offering is expected to raise approximately $53.35 million, which Akso Health Group plans to use for working capital, indicating a move to strengthen its financial position and fund ongoing operations.

Why It Matters

This private placement provides Akso Health Group with a significant cash injection of $53.35 million, which can stabilize its operations and fund future growth, potentially reducing the need for debt financing and improving its financial health.

Risk Assessment

Risk Level: medium — While raising capital is positive, the issuance of new shares and warrants could dilute existing shareholders, and the success of using the funds for working capital depends on effective management.

Analyst Insight

A smart investor would monitor how Akso Health Group deploys the $53.35 million in working capital to assess its impact on operational efficiency and future growth, while also considering the potential for short-term share dilution.

Key Numbers

• $53.35 million — Aggregate Purchase Price (The total amount of capital Akso Health Group expects to raise from this private placement.)
• 160,826,730 — Units Offered (The maximum number of units, each consisting of one ordinary share and one warrant, being sold.)
• $0.3317 — Price Per Unit (The price at which each unit (share + warrant) is being sold to the purchasers.)
• $0.4146 — Warrant Exercise Price (The initial price at which purchasers can buy an additional share using their warrants.)
• $0.0001 — Par Value Per Share (The nominal value assigned to each ordinary share of the Company.)

Key Players & Entities

• Akso Health Group (company) — the registrant and issuer of securities
• Purchasers (person) — certain 'non-U.S. Persons' buying the units
• $53.35 million (dollar_amount) — aggregate purchase price of the offering
• January 17, 2024 (date) — date the Company entered into the securities purchase agreement
• 160,826,730 (dollar_amount) — maximum number of units to be sold

Forward-Looking Statements

• Akso Health Group's working capital will improve significantly in the short term. (Akso Health Group) — high confidence, target: Q1 2024
• The issuance of new shares and warrants may lead to short-term dilution for existing shareholders. (Akso Health Group) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — rdinary Share of the Company, par value $0.0001 per share (“ Share ”) and a
• $0 — uo;) with an initial exercise price of $0.4146, or approximately $1.2438 per Amer
• $1.2438 — ise price of $0.4146, or approximately $1.2438 per American depositary share of the Co
• $0.3317 — ny (“ ADS ”), at a price of $0.3317 per Unit, or approximately $0.9951 per
• $0.9951 — e of $0.3317 per Unit, or approximately $0.9951 per ADS for an aggregate purchase price
• $53.35 million — gregate purchase price of approximately $53.35 million (the “ Offering ”). The net

Filing Documents

• ea191854-6k_aksohealth.htm (6-K) — 15KB
• ea191854ex99-1_aksohealth.htm (EX-99.1) — 214KB
• ea191854ex99-2_aksohealth.htm (EX-99.2) — 94KB
• 0001213900-24-005291.txt ( ) — 324KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Akso Health Group By: /s/ Yilin (Linda) Wang Name: Yilin (Linda) Wang Title: Chief Executive Officer Date: January 22, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR